Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...

(NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...

About the GeneSight Test The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for more than 60 medications commonly prescribed for depression ...

04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc ... access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange benefit ...

Morningstar brands and products Company Portfolio ...